ILTAR, U. Et Al. 2022. Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.2 , 500-503.

ILTAR, U., ALHAN, F. N., VURAL, E., ATAŞ, Ü., SÖZEL, H., DOĞAN, Ö., ... BODUROĞLU, A.(2022). Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.2, 500-503.

ILTAR, UTKU Et Al. "Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.2, 500-503, 2022

ILTAR, UTKU Et Al. "Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.2, pp.500-503, 2022

ILTAR, U. Et Al. (2022) . "Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.2, pp.500-503.

@article{article, author={UTKU ILTAR Et Al. }, title={Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2022, pages={500-503} }